Blue-blocking IOLs damage health

Article

Bevacizumab: less effective against larger lesions; New supranational European society; Happy 50th birthday SOE; Blue-blocking IOLs damage health; 3-D test identifies early stage glaucoma; A new way of tackling ROP; Femtosecond not always appropriate; High pulse pressure linked to OAG; Stem cell project to cure AMD underway; OCT increasingly popular for anti-VEGF monitoring; Glaucoma nano-treatment on the horizon; Lucky for some: the 13th LCA gene; Community optometrists able to diagnose glaucoma accurately; Coffee may prevent blepharospasm

Bevacizumab: less effective against larger lesions

The efficacy of bevacizumab as a treatment for choroidal neovascularization (CNV) is dependent on initial lesion size and the patient's reading ability, according to a report published online ahead of print by the British Journal of Ophthalmology.

Anja Lux and co-workers from the Heinrich Heine University of Duesseldorf, Germany conducted a study to determine the characteristics of non-responders to intravitreal bevacizumab treatment. A total of 43 patients (44 eyes) with visual loss due to CNV received intravitreal injections of 1.25 mg bevacizumab and were followed-up every four weeks for two, three or six months. Re-injections were performed when persistent leakage was observed by fluorescein angiography.

This study suggests that non-responders to intraviteal bevacizumab as a treatment for CNV are likely to be those who have a large initial lesion size.

New supranational European society

Five of the largest European ophthalmic societies have founded a new supranational society - The Federation of European Ophthalmology (FEOph).

The societies involved in the launch of the FEOph are the French Society of Ophthalmology, the German Society of Ophthalmology, the Italian Society of Ophthalmology, the Royal College of Ophthalmologists in the UK and the Spanish Society of Ophthalmology.

Happy 50th birthday SOE

The European Society of Ophthalmology (SOE) celebrated its 50th anniversary at its 2007 Jubilee Congress, held in June, in partnership with the American Academy of Ophthalmology.

At the opening ceremony, Zdenek Gregor, president of SOE, welcomed the 4,000 delegates from 90 different countries and spoke of his pride of a scientific programme that resulted from the active co-operation of more than 40 subspecialty societies and supranational organizations.

José Cunha-Vaz was awarded the 2007 Helmholtz Medal for his contribution to both posterior and anterior segment imaging. During his lecture, Dr Vaz spoke of the importance of the invention of the ophthalmoscope saying the discovery "opened the gate to seeing the fundus of the eye".

Blue-blocking IOLs damage health

Blue-blocking intraocular lenses (IOLs) offer no advantages to the eye and could actually cause health problems such as insomnia and depression, according to Martin Mainster, MD speaking at the OSN Rome Symposium in May.

Dr Mainster emphasized how important blue light is to good vision and health. He explained that blue light-sensitive cells synchronize the body's biological clock to environmental day/night cycles, guaranteeing proper hormonal and physiological rhythms. Furthermore, blue light provides 35% of rod-mediated scotopic sensitivity, making it essential for good vision in dim-light conditions.

Dr Mainster also stressed that no evidence has been found of a correlation existing between blue-light exposure and the pathogenesis of degenerative retinal disorders.

3-D test identifies early stage glaucoma

A 3-D computer automated threshold Amsler grid test is able to identify abnormalities characteristic of glaucoma in glaucoma suspects whose achromatic Humphrey visual field test was normal, according to a report published online ahead of print by the British Journal of Ophthalmology.

Paul Nazemi and colleagues from Doheny Eye Institute, University of Southern California, USA examined 66 eyes of 33 patients with risk factors for glaucoma with the recently developed 3-D computer-based threshold Amsler grid test and with standard automated perimetry. Twenty-three eyes of 15 patients with no risk factors were examined as controls.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.